Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Daniel M Geynisman

Showing results (81-90 of 183) with videos related to

Pageof 19
Sort By:
Urologic Oncology|June 7, 2021
A 25 year perspective on the evolution and advances in an understanding of the biology, evaluation and treatment of kidney cancerDaniel M Geynisman, Jodi K Maranchie, Mark W Ball, et al.
Kidney Cancer (Clifton, Va.)|October 19, 2018
The Evolution of Clinical Trials in Renal Cell Carcinoma: A Status Report for 2013-2016 from the ClinicalTrials.gov WebsitePooja Ghatalia, Rebecca Koenigsberg, David Pisarcik, et al.
Pharmacoeconomics|May 14, 2014
Cost-effectiveness analyses of targeted oral anti-cancer drugs: a systematic reviewFabrice Smieliauskas, Chun-Ru Chien, Chan Shen, et al.
Pharmacoeconomics|November 24, 2018
Economic Burden of Renal Cell Carcinoma-Part I: An Updated ReviewChun-Ru Chien, Daniel M Geynisman, Bumyang Kim, et al.
Nature Reviews. Nephrology|April 15, 2015
The hallmarks of cancer: relevance to the pathogenesis of polycystic kidney diseaseTamina Seeger-Nukpezah, Daniel M Geynisman, Anna S Nikonova, et al.
Urologic Oncology|July 20, 2017
Role of collaboration between urologists and medical oncologists in the advanced prostate cancer spaceChethan Ramamurthy, Jamie Doyle, Robert G Uzzo, et al.
Urology|April 5, 2017
Malignant Infiltration of the Penis From Urothelial Carcinoma of the BladderCarmen Tong, Nikolas Daskalakis, Daniel C Edwards, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 20, 2015
Trends in the Cost and Use of Targeted Cancer Therapies for the Privately Insured Nonelderly: 2001 to 2011Ya-Chen Tina Shih, Fabrice Smieliauskas, Daniel M Geynisman, et al.
Clinical Genitourinary Cancer|May 20, 2025
Impact of Renal Function Eligibility Criteria on Clinical Trials and Real-World Survival Outcomes Among Patients With Metastatic Renal Cell CarcinomaXiaoliang Wang, Jill Hasler, Benjamin Miron, et al.
European Urology Focus|July 30, 2017
Molecular and Genomic Profiling to Identify Actionable Targets in Chromophobe Renal Cell CancerPhilip Abbosh, Srinath Sundararajan, Sherri Z Millis, et al.
Pageof 19

Showing results (81-90 of 183) with videos related to

Sort By:
Pageof 19
Urologic Oncology|June 7, 2021
A 25 year perspective on the evolution and advances in an understanding of the biology, evaluation and treatment of kidney cancerDaniel M Geynisman, Jodi K Maranchie, Mark W Ball, et al.
Kidney Cancer (Clifton, Va.)|October 19, 2018
The Evolution of Clinical Trials in Renal Cell Carcinoma: A Status Report for 2013-2016 from the ClinicalTrials.gov WebsitePooja Ghatalia, Rebecca Koenigsberg, David Pisarcik, et al.
Pharmacoeconomics|May 14, 2014
Cost-effectiveness analyses of targeted oral anti-cancer drugs: a systematic reviewFabrice Smieliauskas, Chun-Ru Chien, Chan Shen, et al.
Pharmacoeconomics|November 24, 2018
Economic Burden of Renal Cell Carcinoma-Part I: An Updated ReviewChun-Ru Chien, Daniel M Geynisman, Bumyang Kim, et al.
Nature Reviews. Nephrology|April 15, 2015
The hallmarks of cancer: relevance to the pathogenesis of polycystic kidney diseaseTamina Seeger-Nukpezah, Daniel M Geynisman, Anna S Nikonova, et al.
Urologic Oncology|July 20, 2017
Role of collaboration between urologists and medical oncologists in the advanced prostate cancer spaceChethan Ramamurthy, Jamie Doyle, Robert G Uzzo, et al.
Urology|April 5, 2017
Malignant Infiltration of the Penis From Urothelial Carcinoma of the BladderCarmen Tong, Nikolas Daskalakis, Daniel C Edwards, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 20, 2015
Trends in the Cost and Use of Targeted Cancer Therapies for the Privately Insured Nonelderly: 2001 to 2011Ya-Chen Tina Shih, Fabrice Smieliauskas, Daniel M Geynisman, et al.
Clinical Genitourinary Cancer|May 20, 2025
Impact of Renal Function Eligibility Criteria on Clinical Trials and Real-World Survival Outcomes Among Patients With Metastatic Renal Cell CarcinomaXiaoliang Wang, Jill Hasler, Benjamin Miron, et al.
European Urology Focus|July 30, 2017
Molecular and Genomic Profiling to Identify Actionable Targets in Chromophobe Renal Cell CancerPhilip Abbosh, Srinath Sundararajan, Sherri Z Millis, et al.
Pageof 19